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Background. Secretions accumulate in endotracheal tubes’ (ETT) lumens upon their placement in patients. (e secretions impact
airway resistance and pressure. Secretions potentiate prolongedmechanical ventilation and ventilator-associated pneumonia. Our
primary objective in this study was to evaluate an ETT-clearing device (ETT-CD) in its ability to remove secretions from ex vivo
ETT lumens.Methods. Forty ETTs, obtained from intensive care patients at extubation, were individually placed into a ventilator
field performance testing simulator at 37°C. (e pressure drop through the ETTs was measured at a flow rate of 60 L/min before
and after cleaning with the ETT-CD and compared with unused, similarly sized controls tubes. (e ETT-CD was inserted into an
ETTuntil the tip reached Murphy’s eye (hole in the side) of the ETT. (e wiper, set back from the tip, was expanded by ETT-CD
handle activation. As the ETT-CD was removed, the distal wiper extracted secretions from the ETT lumen. Results. Forty ETTs
were tested with nonparametric Wilcoxon signed-rank tests. Before being cleared with the ETT-CD, the median pressure drop in
the extubated 7.5mm ETTs was 17.8 cm H2O; after ETT-CD use, it was 12.3. (e cleared ETTs were significantly improved over
the ETTs before being cleared (p< 0.001); however, there remained a significant difference between the cleared ETTs and the
control tubes (p � 0.005), indicating the clearing was not to the level of an unused ETT. Similar results were determined for the
8.0mm ETTs. Conclusions. For the 7.5mm and the 8.0mm EETs, the ETT-CD improved effective patency of the ETTs over the
uncleared ETTs, independent of occlusion location, tube size, or length of tube. However, there remained a significant difference
between the cleared tubes and controls.
1. Introduction
(e physical and economic burdens of ventilator-associated
pneumonia (VAP) have been well documented and recog-
nized as major consequences of mechanical ventilation
(MV). VAP has significant morbidity, mortality, and cost
[1]. (e financial burden and demand upon resources are
between approximately $40,000 and $90,000 per mechan-
ically ventilated patient [2]. Patients’ quality of life is im-
pacted by VAP discomfort and the burden of additional
hospital stay. Depending upon how VAP is defined, it occurs
in approximately 10% [3] of adults aged 65 years and above.
(e VAP incidence has been relatively stable and high [3].
(us, there is a critical need to develop new preventative
strategies against the development of VAP in mechanically
ventilated patients.
Initially, preventative strategies for VAP were focused on
the positive pressure ventilator and reducing microbial
contamination with heating elements in the airway tubing
[4]. Antimicrobial therapy was (and is) used routinely in the
management of VAP in critically ill patients. However, due
to the emergence of multidrug-resistant or extremely drug-
resistant pathogens [5], alternatives to antimicrobial ther-
apies are needed. (erefore, the focus began to change to
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limiting biofilm development and/or reducing biofilm load
and secretions in the lumens of endotracheal tubes (ETT)
through the use of noninvasive management teams to
monitor patients onMVwith daily oral infection control [6].
(e concept is valid, although healthcare personnel com-
pliance with such protocols is problematic [7].
(e secretions, including oral microflora, create a bio-
film which has the potential to accumulate above the ETT
cuff. (ese secretions then enter the ETTproper and adhere
to the ETT lumen causing a constriction [6, 8]. Constriction
of the lumen results in airway resistance and pressure drop
in ETT during MV.
An ETT lumen during MV is a consistent surface for
microbial colonization since the ends of an ETT are under
constant parallel lines of force, while the central curve of the
tube experiences a vortexing action [9]. As the biofilm
develops and secretions adhere, the lumen of an ETT oc-
cludes and narrows. To clear secretions from the ETT lumen,
closed-system suctioning is periodically employed [10].
However, it was reported that the incomplete removal of
secretions during suctioning was found to be a factor in the
narrowing of an ETT’s lumen [11, 12].
Secretions and biofilms accumulate quickly and un-
predictably [13, 14]. When they detach from the luminal
ETT, they can project deep within the lungs (up to 45 cm
from the end of the ETT) [15]. It should be noted that, in
addition to an ETT having secretions that can enter the
lungs, oral bacteria may migrate quickly from the mouth
during intubation and contribute to VAP pathogenesis [16].
ETT lumenal occlusion with biofilm and secretion,
which is unpredictable of MV time [17], may result in VAP
or other infections in the lungs. (is should be considered
when weaning is difficult, even for patients ventilated for less
than one day [18]. ETT obstruction may mislead clinicians
on the readiness of patients for extubation and subsequently
lead to unnecessary prolongation of intubation and MV
[19, 20].
In the designed study, we hypothesized that using a novel
federally registered medical device to clear biofilm secretions
from the ETT lumens would return the ETT to luminal
patency. To test this hypothesis, we designed a study aimed
at measuring the impact of an ETT clearing device (ETT-
CD) (EndOclear® Restore™ device, previously namedEndOclear® endotracheal tube clearing device) withincontrolled ex vivo conditions. To demonstrate an ex vivo
model, we designed a multistation ventilator field perfor-
mance testing simulator for data acquisition.
2. Materials and Methods
(is study was conducted at West Virginia University
Hospital in association with the Department of Pathology
and was approved by the West Virginia University In-
stitutional Review Board (IRB H-23234). Forty ETTs were
randomly obtained from adult patients at the time of
extubation from a combined Medical/Surgical Intensive
Care Units (MICU/SICU). All ETTs of adult patients (age
>18 years old) were eligible for collection, unless the patient
was diagnosed with tuberculosis and/or HIV. Patient
medical histories, dates, times of intubation and extubation,
length of ETT intubation (days), and clinical and ventilator
information were recorded in a database.
2.1. Ex Vivo Measurements. (e setting, testing design, and
calibration method of the pressure drop test apparatus were
published previously [13]. (e simulation device was
modified with an engineered heat-regulated tracheal feature
with a temperature sensor probe to maintain the ex vivo
ETTs at 37°C (body temperature) while conducting the
research. Additionally, the new design included the posi-
tioning of the engineered heated head at a 30° anatomically
correct head position following Institute for Healthcare
Improvement guidelines that would be in place during
patient care. (e modificated design is referred to as the
multistation ventilator field performance testing simulator
(Supplemental Figure 1). (e setup closely duplicated the in
vivo anatomy and temperature of a human who has an ETT
in place allowing for themeasure of the true impact of airway
resistance of the ex vivo ETTs.
2.2. Control Tubes. Standard ETTs (Hi-Lo; Mallinckrodt,
Inc; St. Louis, MO) sizes at 6.5, 7.0, 7.5, and 8.0mm internal
diameter were evaluated and used as baseline controls. Each
control ETT was placed and secured, by cuff inflation, into
the multistation ventilator field performance testing simu-
lator set at 37°C. A high-efficiency particulate arresting
(HEPA) air breathing filter (Iso-Gard® HEPA Light 28022;
Hudson RCI; Temecula, CA) was attached to the proximal
end of each control tube for consistency when comparing
the control tube with a patient’s ex vivo tube, as the ex vivo
tubes needed the HEPA filter to minimize potential exposure
to biohazard material.
Pressure drop was measured by opening an air flow
control valve of compressed air set to a pressure of 2109 cm
H2O (30 pounds per square inch, psi) at a controlled rate
from 0 to 100 liters per minute (L/min) over 30 seconds.
Data acquisition of the mass flow rate through the mass flow
meter and pressure transducer (PTS-2000; Mallinckrodt,
Inc; St. Louis, MO), using specialized software (Puritan
Bennett Breathlab™ PTS Respiratory Products Test Soft-
ware, V. 2.0 Rev. B; Mallinckrodt, Inc), was set to 72
measurements per second. (e collected pressure drop data
were repeated three times, averaged, logged, analyzed, and
evaluated at 30, 60, and 90 L/min for reliability (Supple-
mental Figure 2). We focused on 60 L/min as this flow rate
achieved optimal gas exchange in most critically ill, intu-
bated adult patients [21, 22].
2.3. Sample Tubes. Extubated ETTs were collected and im-
mediately placed in a biohazard bag with sterile gauze wetted
with 4ml of sterile saline and sealed to avoid de-
humidification during the transportation to the laboratory.
Using the same methods as for the control tubes, the ex vivo
ETTs were connected to the multistation ventilator field
performance testing simulator set at 37°C. (e initial set of
pressure drop data (cm H2O), referred to as the before
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clearing data (pre), was obtained using the same method as
for the control tubes.
(en, each ex vivo ETTwas cleared with the ETTclearing
device (ETT-CD) (EndOclear® Restore™ device, endOclear®,Inc., PetoskeyMI), a federally registered (FRDoc. 2011–21685
Filed 8-23-11; 8:45 am) medical device. (e ETT-CD was
designed with a flexible central tube and a smooth disc-
shaped wiper at its distal end (Supplemental Figure 3). (e
ETT-CD was inserted into the ETT until the tip reached
Murphy’s eye (hole in the side) of the ETT. (e disc-shaped
wiper, set back from the tip, was expanded by activating the
handle of the device (Supplemental Figure 4). Once deployed,
the wiper is firmly engaged with the inside walls of the ETT, in
its activation mode. (e ETT-CD was then removed,
extracting biofilm secretions with the wiper. (e insertion,
positioning, and clearing of the ETT (distal end first) required
approximately 8 seconds. A second set of pressure drop data
(cmH2O), referred to as the cleared data (post), were obtained
using the same method as for the control and preclearing
ETTs data collection procedures.
2.4. Statistical Analysis. Data were organized by tube size.
Pressure drops were tabulated and compared with the size-
matched control tubes [13]. JMP v. 9.0.0 and SPSS version 20
(SAS Institute Inc; Cary, NC) software were used to perform
data analyses. Nonparametric statistical tests were used due
to sample size. Related-samples Wilcoxon signed-rank tests
were used to compare the ETTs before being cleared and
after being cleared. One sample (vs. median control pressure
drop) Wilcoxon signed-rank tests was used to compare the
control tubes with the ex vivo tubes before clearing and after
clearing. Significance was accepted at an alpha of <0.05.
3. Results
Studied ex vivo ETTs were from 23 male and 17 female
patients with a mean patient age of 53 years (SD ± 18). (e
ETTs were from 15 patients diagnosed with pneumonia, 10
with a history of smoking, 12 with COPD, 22 who had fever,
and 30 who received antibiotic therapy. Eight ETTs were
reintubations and 31 ETTs were from patients who were on
MV over 48 hours. Respiratory failure was the most prev-
alent reason for intubation. (e collected ETTs had been in
use for a mean of 2.6 days of intubation and were composed
of three sizes: 7.0; 7.5; and 8.0mm (Table 1).
3.1. Before Clearing the Ex Vivo ETTs versus Control Tube
Results. (ere was a significant difference between the ex
vivo ETTs’ before being cleared and the control tubes in-
dicating obstruction in the ex vivo ETTs as compared with
the control tubes for sizes 7.5mm and 8.0mm (p< 0.001).
(ere was no significant difference between the size 7.0mm
ex vivo ETTs and the control tubes (p � 0.068).
3.2. Before Clearing the Ex Vivo ETTs versus the Cleared Ex
Vivo ETTs Results. (e overall median pressure drop for the
ex vivo ETTs (n � 40) before clearing was 17.5 cm H2O
(minimum � 10.2 cm H2O; maximum � 77.8 cm H2O). (e
overall median pressure drop after clearing was 11.4 cmH2O
(minimum � 9.5 cm H2O; maximum � 16.8 cm H2O).
(ere was a significant difference in the ex vivo ETT
lumens before being cleared and after being cleared for sizes
7.5mm and 8.0mm tubes (p< 0.001), indicating a difference
in pressure drop due to lumen obstruction being cleared
after the use of the ETT-CD. (ere was no significant dif-
ference in the 7.0mm tubes. (e results are summarized in
Table 2.
3.3. Cleared Ex Vivo ETTs versus Control Tubes Results.
(ere was significant difference in the cleared ex vivo ETT
lumens and the control tubes for the sizes 7.5mm and
8.0mm (p< 0.001), indicating a difference remained in
pressure drop between the cleared tubes and the control
tubes. (ere was no significant difference in the 7.0mm
tubes.
(e majority of the cleared ET tubes were within 5–13%
of the pressure drop observed in control tubes. Utilization of
the ETT-CD resulted in a 22–145% decrease in pressure drop
in all ET tubes at 60 L/minute. (e average percent increase
in pressure drop from control tubes for the remaining flow
rates at sizes 7.0, 7.5, and 8.0mm are displayed in Supple-
mental Figure 5.
Pressure drop data from ETTs before clearing were
compared to control tubes to assess functionality of a smaller
tube size at 60 L/min. 1 of 4 ETTs (7.0mm), 11 of 17 ETTs
(7.5mm), and 14 of 19 ETTs (8.0mm) had a pressure drop
equivalent to 1 size smaller. ETT sizes 7.5mm and 8.0mm
presented greater pressure drops compared to controls of
smaller sizes. 7 of 17 ETTs (7.5mm) and 12 of 19 ETTs
Table 1: Characteristics of the study population.
Variable Mean (SD)
Age ± SD 53.02 (17.89)
Height (in.) 67.59 (4.73)
Weight (kg) 86.18 (31.13)
Hospital LOS (days) 17.5 (12.42)
ICU LOS (days) 8.8 (6.90)
Vent days 3.1 (2.49)
LOI (days) for ETTs obtained 2.60 (2.32)
History n (% of total)
Male patients 23 (57.5%)
Female patients 17 (42.5%)
Smokers 10 (25.6%)
Patients on antibiotic therapy 30 (81.08%)
Patients on ventilator >48 hours 31 (77.5%)
Comorbidities
Reintubation 8 (20.0%)
Pneumonia prior to intubation 9 (22.5%)
Pneumonia following intubation 13 (32.5%)
Total pneumonia 15 (37.5%)




Respiratory failure 21 (52.5%)
Others (surgery, respiratory arrest, drug OD) 19 (47.5%)
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(8.0mm) had a pressure drop equivalent to 2 sizes smaller.
Detailed percentage of ET tubes functioning at smaller sizes,
prior to clearing, is outlined in Supplemental Table 1.
4. Discussion
Forty extubated ETTs were randomly obtained from
mechanically ventilated adult patients from a combined
Medical/Surgical Intensive Care Units (MICU/SICU). (e
ETTs were placed into a simulator’s anatomical trachea,
duplicating in vivo placement, thereby creating a more re-
alistic experimental platform. (e ETT-CD improved the
effective patency of cleared ETTs versus ETTs before clearing
for the 7.5mm and 8.0mm (p< 0.001); however, compared
with control tubes, some secretion remained (p< 0.001).(e
ETT-CD was effective in this study in improving the
pressure change between the 7.5mm and 8.0mm ETTs
before being cleared and after being cleared through the
entire length of the tube, experiencing no issues in the
navigation of the curvature of the simulated anatomical
trachea while the head was in the 30° resting position.
Significant obstruction to respiratory flow begins within
hours following tracheal intubation as a result of biofilm
occlusion within the ETTs’ lumen. Biofilm occlusion in the
ETT lumen results from the accumulation of secretions and
from the colonization of fungal and bacterial organisms
[23, 24]. Researchers have shown that contaminated oro-
pharyngeal secretions and/or gastric contents pool above
the inflated ETT cuff in the subglottic space, causing
microaspiration, tracheobronchial colonization, and VAP
incidence [25, 26]. Leakage of subglottic secretions around
the cuff (between ETTand tracheal mucosa) reach the distal
airways within hours following endotracheal intubation [13,
26–30]. Once in the distal airways, contaminated secretions
and biofilm can move more easily within the lungs. Biofilm,
itself, acts as a nidus for inoculation in the lower respiratory
tract, with the potential for VAP [26, 31, 32]. VAP is as-
sociated with prolonged hospitalizations, increased length of
stay in an ICU, and increased costs.
To address these problems, a number of long established
and innovative modifications to respiratory care and
medical treatment practices have been developed to improve
artificial airways, limit airway contamination, decrease in-
fection rate, reduce airway resistance, return ET tube pa-
tency, and improve outcomes of mechanically ventilated
patients. Currently, the institutional standard of care
commonly used to clear secretions from an ETT is blind
tracheal suctioning through a closed system [33, 34]. (is
maneuver, however, has been found to be poorly effective, as
the literature has shown blind suctioning to decrease lung
volume leading to hypoxia, trigger cardiac arrhythmias,
increase intracranial pressure, and detach aggregates of ETT
biofilm into the lower respiratory tract [26, 33]. Several
researchers [33], also found a significant degree of ETT
luminal obstruction in intubated patients despite optimal
humidification and standard ETT suctioning.
To combat the collection of contaminated secretions
above the ETT cuff, subglottic suctioning was established.























All controls 3 10.8 0.27 n/a −8.63 <0.001
Extubated, not
cleared (pre) 40 21.8 13.30 10.2 77.8 5.27 <0.001 4.80 <0.001
Extubated, cleared
(post) 40 11.8 0.29 9.5 16.8 −8.63 <0.001 n/a
7.0mm diameter
Control 1 14.5 0.14 n/a −3.69 0.035
Extubated, not
cleared (pre) 4 19.2 1.88 16.4 20.4 4.94 0.016 5.20 0.014
Extubated, cleared
(post) 4 15.9 0.75 15.0 16.8 −3.69 0.035 n/a
7.5mm diameter
Control 1 11.8 0.01 n/a −3.30 0.004
Extubated, not
cleared (pre) 17 24.1 9.12 12.0 46.0 4.33 <0.001 4.13 0.001
Extubated, cleared
(post) 17 12.5 0.86 11.4 14.3 −3.30 0.004 n/a
8.0mm diameter
Control 1 9.1 0.04 n/a −10.76 <0.001
Extubated, not
cleared (pre) 19 23.0 17.42 10.2 77.8 3.55 0.002 3.23 0.004
Extubated, cleared
(post) 19 10.3 0.48 9.5 11.3 −10.76 <0.001 n/a
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Subglottic suctioning is a method that requires the use of a
modified ETT with subglottic suction capability. It is rec-
ommended for patients who require more than 72 hours of
mechanical ventilation [34, 35]. Subglottic suctioning has
been shown to cause tracheal mucosa damage, as well as,
tracheal injury immediately adjacent to the subglottic suc-
tion [22, 25, 35]. Suction dysfunction has raised concerns
about safety, as dysfunction has been attributed to ob-
struction of the subglottic suction port by suctioned tracheal
mucosa [26, 35].
In recent years, several researchers and companies have
focused their efforts to develop novel medical devices
(e.g., Mucus Shaver, Obstruction Remover, Mucus Slurper,
and Rescue Cath), different from suctioning, aimed spe-
cifically at cleaning the ETT lumen by removing secretions
attached to the ETT by physically scraping or wiping the
internal surface of the ET tube [12, 25, 33]. Acoustic re-
flectometry, high-resolution computed tomography [33],
intraluminal catheter, pressure oscillation analyses [36],
sound analysis [37], and resistive work of breathing are all
methods used to evaluate modified ETTs and ETTdevices by
researchers. Although potential benefits may exist, most
studies involved partial assessments of the ETT, which in
turn could potentially affect the validity and efficacy of the
method. In addition, large clinical trials and laboratory
studies have been limited in the testing of these medical
devices as they lack accurate measurements of ETT patency
and have not provided concrete evidence for wide use
[12, 33, 34, 38].
Our study aimed at overcoming the shortcomings of
previous trials by a more rigorous design and at developing a
standardized testing procedure to measure the impact of an
ETT-clearing device (ETT-CD) in returning the ETT to
luminal patency within controlled ex vivo conditions.
Mietto et al. [12] estimated that the average loss of
intraluminal ETT volume from partial occlusion due to
secretion accumulation was between 9 and 15%. Our results
estimated that nearly 25% of ET tubes at size 7.0mm, 65% at
size 7.5mm, and 74% at size 8.0mm had a measurable
pressure drop equivalent to one size smaller. More apparent
was the decrease in pressure drops in ETTtubes sizes 7.5mm
and 8.0mm where 41% of 7.5mm and 63% of 8.0mm were
estimated to function at the same value as ETTs two sizes
smaller. We did not find any underlying factors associated
with the increase in biofilm secretions within the ETT lu-
men. We did, however, find a positive correlation between
the volume extracted from the ETT lumen and pressure drop
observed in the multistation ventilator field performance
testing simulator, independent of LOI.
Unlike Glass et al. [11], who predicted the longer the
time an ETT was in place, the greater the opportunity for
debris to accumulate, our findings closely matched those of
Wilson et al. [13], who illustrated the unpredictable nature of
ET tube obstruction and its independence of LOI. Consistent
with Wilson et al.’s findings [13], a patient intubated 3 hrs or
300 hrs could have either significant increases in resistance
or measurements equivalent to those of size-matched
control tubes. (e amount of biofilm secretions within
the ETT lumen was not a time-related event [13]; hence,
partial occlusion due to secretion accumulation cannot be
recklessly ignored.
Our results show that ex vivo ET tubes, before clearing,
had pronounced pressure drops (and therefore a higher
degree of resistance) of 32–158% from control tubes at the
7.5mm and 8.0mm luminal sizes. We tested the efficacy,
safety, and feasibility of the ETT-CD in an ex vivo model,
which reduced luminal biofilm secretions of ETTs to within
5–13% of the pressure drop observed in control tubes. Not
only was the ETT-CD found to be easy to use but it also was
effective in removing secretions from the ETT lumens in the
7.5mm and 8.0mm tubes.
4.1. Limitations. Although the sample size (n � 40) was
adequate for statistical observations regarding device impact
and clinical associations, the small sample number of size
7.0mm ETTs (n � 4) limits our findings for that diameter
ETT; nevertheless, consistent results were found for all of the
ETTs studied. Moreover, the study was not powered to
evaluate the efficacy of the ETT-CD to respiratory care and
medical treatment practices, such as, standard suctioning.
(e study was designed to evaluate the ETT-CD and its
ability to remove luminal biofilm secretions and thereby
increase patency of the ETT. Larger studies are needed to
determine whether the use of the ETT-CD has any effect on
VAP incidence, mortality, duration of MV, and ICU or
hospital stay.(e three ETTsizes collected and tested against
the ETT-CD had internal diameters of 7.0, 7.5, and 8.0mm
because these are the ETTsizes used for adults in ourMICU/
SICU. Additional studies are needed to validate ETT-CD
functionality in smaller ETTs, as well as, comparative studies
against blind tracheal suctioning through a closed system,
the institutional standard of care.
5. Conclusion
Within hours following tracheal intubation, ETTs in MV
patients begin to accumulate luminal biofilm secretions
causing narrowing or even occlusion of the ETT, as pre-
viously reported.(e extent of the biofilm accumulation and
occlusion in any one patient is unpredictable. (e ETT-CD
was designed to clear the lumen of the ETTwhile the tube is
functioning as a conduit airway from the patient’s trachea to
the mechanical ventilator without the use of antimicrobials.
(e newly designed multistation ventilator field perfor-
mance testing simulator allowed for a more representative
means to evaluate the impact of any clearing device in re-
ducing airway resistance. Following the use of the ETT-CD,
the 7.5mm and 8.0mm ex vivo ETTs in the study were
significantly improved over the ETTs before being cleared,
independent of occlusion location, tube size, or length of
tube.
Data Availability
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Supplementary Materials
Supplemental Table 1: functionality of uncleared ETTs in
relation to ETT size. Supplemental Figure 1: schematic
representation of the multistation ventilator field perfor-
mance testing simulator. (e simulator is organized into
four regions for quality control used in evaluating pressure
drop (before and after clearing) accompanied by a step-by-
step schematic representing placement of extubated ETT
from 37°C “heated head” to PTS-2000. Supplemental Fig-
ure 2: measured pressure drop of each extubated patient
endotracheal tube; control, before the ETTwas cleared (pre),
and after the ETT was cleared (post) evaluated at flow rates
of (A) 30 L/min, (B) 60 L/min, and (C) 90 L/min. Supple-
mental Figure 3: exact representation of the endOclear
endotracheal tube-clearing device (ECCD). (e endOclear
endotracheal tube-clearing device is composed of four
components: (A) depth stop, (B) red safety toggle, (C)
handle and trigger to deploy wiper, and (D) wiper, (D1)
wiper closer, and (D2) wiper deployed. Supplemental Fig-
ure 4: schematic representation of the endOclear endotra-
cheal tube-clearing device. Positioning of the ECCD in the
ETT: (1) bullet-shaped tip of the flexible central tube reached
Murphy’s eye of the ETT, (2) the disc-shaped wiper, set back
from the tip, and (3) activating handle of device deploys
wiper. (e ECCD is pulled back out of the tube, extracting
biofilm secretions clearing the ETT. Supplemental Figure 5:
comparison of the average percent (%) increase in pressure
drop of ETTs (before and after clearing) from control ET
tubes for each sized ETT, 7.0, 7.5, and 8.0mm at flow rates,
30, 60, and 90 L/min. (Supplementary Materials)
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